Publications by authors named "A Fujino"
Background: Diabetic kidney disease (DKD) is one of the typical complications of type 2 diabetes (T2D), with approximately 10 % of DKD patients experiencing a Rapid decline (RD) in kidney function. RD leads to an increased risk of poor outcomes such as the need for dialysis. Albuminuria is a known kidney damage biomarker for DKD, yet RD cases do not always show changes in albuminuria, and the exact mechanism of RD remains unclear.
View Article and Find Full Text PDFPurpose: This study aimed to investigate the current practices in the diagnosis and surgical management of anorectal malformations (ARMs) in female patients in Japan, specifically focusing on anovestibular fistula (AVF), rectovaginal fistula (RVF), and persistent cloaca (PC).
Methods: An anonymous online survey was conducted with 61 institutional members of the Japanese Study Group for Anorectal Anomalies.
Results: Sixty-one institutions (100%) completed the survey.
Background: Anticoagulation therapy for atrial fibrillation (AF) has undergone major changes following the introduction of direct oral anticoagulants (DOAC) in 2011. However, the transition of anticoagulation therapy for AF patients with severe renal dysfunction remains to be elucidated.
Methods And Results: Follow-up data, including creatinine clearance (CrCl), were available for 3,706 patients in the Fushimi AF Registry.
Article Synopsis
- A population pharmacokinetic analysis was performed on data from 215 Japanese subjects taking oral sirolimus, identifying factors that affect the drug's pharmacokinetics across different age groups, including neonates, infants, and adults.
- The study found that sirolimus levels increased with higher hemoglobin and that the granule form had significantly higher exposure than the tablet form, while certain drugs decreased its levels significantly.
- The PopPK model developed can help customize sirolimus dosing for individuals based on their age and body weight to ensure effective treatment within the proper concentration range.
Article Synopsis
- - The study explores how NSCLC patients with poor performance status and symptomatic brain metastases can benefit from upfront intracranial treatment, potentially leading to improved overall survival.
- - Data from 50 patients showed that those treated with tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICI) had better median survival rates (19 months) than those receiving chemotherapy alone (13 months).
- - Results suggest that even patients initially deemed unsuitable for ICI may experience improved survival with personalized treatment approaches, evidenced by significant differences in outcomes based on the type of systemic therapy chosen.